Prophylactic Factor Replacement Versus on‐Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10‐Year Follow‐up
Haemophilia · 2026-11 · 32 (6) · 1513-1521
DOI: 10.1111/hae.70351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 05.07.2026. Verfasst von Zhongyu Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Peking Union Medical College Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Hemophilia A. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The long‐term benefits of prophylactic factor replacement following total knee arthroplasty in patients with hemophilia remain insufficiently evaluated.
Methods
This retrospective cohort study included 70 patients (108 knees) with hemophilia A or B who underwent primary total knee arthroplasty (TKA) between January 2003 and October 2020. Based on their long‐term postoperative pattern of factor replacement therapy, patients were classified into the prophylactic group and the on‐demand group. Patient‐reported outcomes (WOMAC, VAS, FJS‐12, and satisfaction scores) were compared between the two groups. Kaplan–Meier survival analysis was conducted to compare prosthesis survival between groups.
Results
Over a mean follow‐up period of 9.7 years (range, 5 to 22 years), the prophylaxis group demonstrated superior clinical outcomes compared to the on‐demand group, with lower WOMAC total scores (14.9 vs. 20.1, p = 0.03) and higher satisfaction scores (17.7 vs. 15.2, p < 0.01), greater ROM (93.5° vs. 60.3°, p < 0.01), and less flexion contracture (5.3° vs. 13.0°, p < 0.01). Kaplan‐Meier survival analysis indicated superior prosthesis survival in the prophylaxis group (HR = 0.19, 95% CI: 0.06–0.56, p = 0.01). Restricted cubic spline (RCS) demonstrated that when the annual joint bleeding rate (AJBR) exceeded 4 episodes per year, the odds ratio for adverse clinical outcomes was greater than 1.
Conclusion
Long‐term prophylactic factor replacement after primary TKA seemed to optimize surgical outcomes and improve prosthesis survival. However, due to the limitations of this study, its conclusions should be confirmed by future, better‐designed studies (prospective, double‐blind, randomized).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, Peking Union Medical College Hospital, Beijing, People's Republic of China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
- Department of Breast surgery, Peking Union Medical College Hospital, Beijing, People's Republic of China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Luo, Z., Zhong, X., Zhang, C., Feng, B., & Weng, X. (2026). Prophylactic Factor Replacement Versus on‐Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10‐Year Follow‐up. Haemophilia, 32(6), 1513-1521. https://doi.org/10.1111/hae.70351
Vancouver
Luo Z, Zhong X, Zhang C, Feng B, Weng X. Prophylactic Factor Replacement Versus on‐Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10‐Year Follow‐up. Haemophilia. 2026;32(6):1513-1521. doi:10.1111/hae.70351
BibTeX
@article{Luo2026,
author = {Luo, Zhongyu and Zhong, Xiaoying and Zhang, Chen and Feng, Bin and Weng, Xisheng},
title = {Prophylactic Factor Replacement Versus on‐Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10‐Year Follow‐up},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {6},
pages = {1513--1521},
doi = {10.1111/hae.70351}
}
EUVIMED